文献速递腹部CTMR

CT/MRI评估的肌少症与非肝硬化原发性胆汁性胆管炎患者治疗应答及临床结局的相关性

Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients.
PubMed 文献 · Eur J Radiol · 2025-04-03

回顾性纳入2009年1月至2023年12月连续就诊的164例非肝硬化原发性胆汁性胆管炎患者,通过L3层面CT/MRI骨骼肌指数评估肌少症,发现肌少症患病率40.2%,肌少症患者UDCA治疗12个月生化应答率更低(45.9% vs 65.9%,P=0.014),随访期间肝脏相关事件发生率更高(24.2% vs 11.2%,P=0.027)。

要点

  • 非肝硬化PBC患者中肌少症患病率为40.2%,合并肌少症者UDCA治疗12个月生化应答率更低。
  • 肌少症患者随访期间肝脏相关事件发生率更高(24.2% vs 11.2%,P=0.027)。
  • 肌少症组基线和肝脏CRP、IL-6水平更高(P<0.05)。

核心结论

  • 肌少症在非肝硬化PBC患者中高度流行,合并肌少症可能对UDCA治疗的生化应答及无肝硬化PBC患者肝脏相关不良事件的发生产生不利影响。

研究设计与样本

  • 回顾性研究,纳入2009年1月至2009年12月连续就诊的非肝硬化PBC患者164例,通过治疗前L3层面CT或MRI计算骨骼肌指数评估肌少症,比较基线和UDCA治疗后应答率及肝脏相关事件。

诊断标准与关键数值

  • 采用治疗前L3层面CT或MRI的骨骼肌指数(SMI)评估肌少症,164例中66例(40.2%)识别为肌少症。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: Sarcopenia is a common complication in patients with cirrhosis. However, research on sarcopenia in patients with noncirrhotic primary biliary cholangitis (PBC) is limited. This study aimed to investigate the prevalence of sarcopenia and the associations between concomitant sarcopenia and the biochemical response to ursodeoxycholic acid (UDCA) treatment and clinical outcomes in patients with noncirrhotic PBC.

METHODS: This retrospective study enrolled consecutive patients whose baseline visits occurred between January 2009 and December 2023. Sarcopenia was assessed via pretreatment CT or MRI at the mid-L3 level through the skeletal muscle index (SMI). Baseline characteristics, response rate after UDCA administration, liver-related events were compared. And baseline liver and plasma C-reactive protein (CRP) and IL-6 levels in a subset of patients were also evaluated.

RESULTS: A total of 164 patients were included and sarcopenia was identified in 66 (40.2 %) patients. The median duration of follow-up was 4.75 (1.71, 6.40) years. The PBC patients with sarcopenia had a lower biochemical response rate (45.9 % vs. 65.9 %; P = 0.014) after 12 months of UDCA treatment and a higher incidence of liver-related events (24.2 % vs. 11.2 %, P = 0.027) during follow-up. Furthermore, higher levels of baseline CRP and IL-6 in the plasma and liver were also observed(P < 0.05).

CONCLUSIONS: Sarcopenia was highly prevalent in patients with noncirrhotic PBC. Concomitant sarcopenia may adversely affect the biochemical response to UDCA treatment and the occurrence of liver-related adverse events in PBC patients without cirrhosis.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhou L, Li B, Wang Z, et al. Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients. Eur J Radiol. 2025. PMID: 40220738. doi:10.1016/j.ejrad.2025.112094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。